Phaseline

Targets › APOB

APOB (Apolipoprotein B-100): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 4 Phase 3, 2 Phase 1, 2 Phase 2; Metabolic and endocrine, Neurology, Infectious disease; next expected readout Nov 2026.

Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. (UniProt, P04114)

Open in Phaseline: the race on APOB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vir BiotechnologyElebsiran
Apolipoprotein B (APOB) antisense oligonucleotide inhibitor
APOBPhase 3Viral HepatitisNov 2026
Beijing Suncadia PharmaceuticalsSHR-1918
APOB mRNA antisense oligonucleotide
APOBPhase 3Hypertriglyceridemia; Hyperlipidemia; HypercholesterolemiaMar 2027
Arrowhead PharmaceuticalsARO-DIMERPA
Antisense oligonucleotide (ASO) targeting apolipoprotein B mRNA
APOBPhase 1Hyperlipidemia; MixedJul 2027
Alnylam PharmaceuticalsALN-5288
apolipoprotein B (APOB) mRNA silencing agent
APOBPhase 1Alzheimer's DiseaseMar 2030

Conditions

Viral Hepatitis (3) Alzheimer's Disease (1) Hypertriglyceridemia (1) Hyperlipidemia (1) Hypercholesterolemia (1) Hyperlipidemia; Mixed (1)

Modalities

small molecule (3), mixed (1)

Companies

Alnylam Pharmaceuticals (1) Beijing Suncadia Pharmaceuticals (1) Vir Biotechnology (1) Arrowhead Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.